RU-2861532-C1 - METHOD FOR EARLY DIAGNOSIS OF OBLIGATE PRECANCEROUS DISEASES OF ORAL MUCOSA

RU2861532C1RU 2861532 C1RU2861532 C1RU 2861532C1RU-2861532-C1

Abstract

FIELD: medicine; dentistry; oncology. SUBSTANCE: invention can be used for the early diagnosis of obligate precancerous diseases of the oral mucosa. Carrying out a visual examination and staining of the affected areas of the oral mucosa using a special indicator dye. The dye is obtained by mixing 72-75% blueberry extract and 25-28% 10% ascorbic acid and is applied to the oral mucosa using a dental microbrush, after 5 minutes the area is washed with a swab moistened with water. And when persistent signs of staining of pathologically altered cells of the spinous layer of the epithelium are detected on the mucosa, obligate precancerous diseases are diagnosed. EFFECT: timely treatment, prevention of process malignisation and preservation of the patient's quality of life due to early detection of pathologically altered tissues. 1 cl, 4 dwg, 1 ex

Inventors

Ushnitskii Innokentii Dmitrievich
Egorov Anton Nikolaevich
Soloveva Marianna Innokentevna
Nikolaeva Tatiana Ivanovna
Egorova Liudmila Ivanovna
VASILEV VLADIMIR NIKOLAEVICH

Dates

Publication Date: 20260505
Application Date: 20250605

Claims (1)

A method for early diagnosis of obligatory precancerous diseases of the oral mucosa, including staining the mucous membrane using a dye, characterized in that the dye is obtained by mixing blueberry extract - 72-75% and 10% ascorbic acid - 25-28%, the affected areas of the oral mucosa are stained with the resulting dye using a dental microbrush, after 5 minutes the stained area is washed with a swab moistened with water and, based on persistent signs of staining, obligatory precancerous diseases of the oral mucosa are diagnosed.

Description

The invention relates to dentistry and can be used in the early diagnosis of precancerous diseases of the oral mucosa for the timely and prompt implementation of comprehensive medical and social rehabilitation and the prevention of their complications. A method for diagnosing precancerous diseases of the oral mucosa is known (RU (11) 2737523(13) C1, G01N 21/3577, published 01.12.2020), including examining a sample of oral fluid using instrumental research methods, characterized in that an IR spectroscopic study of the oral fluid is carried out in the spectral region of 1200-1000 cm -1 , while the sample is dried, the dry residue is crushed and suspended in vaseline oil, the height of the absorption band peaks with maxima at 1165, 1160, 1150, 1140, 1130, 1080, 1040, 1030 cm -1 is determined, the value of the ratio of the height of the peak with a maximum at 1150 cm -1 to the height of the peak with a maximum at 1165 cm -1 is calculated, the value the ratio of the height of the peak with a maximum at 1150 cm -1 to the height of the peak with a maximum at 1080 cm -1 , the value of the ratio of the height of the peak with a maximum at 1140 cm -1 to the height of the peak with a maximum at 1160 cm -1 , the value of the ratio of the height of the peak with a maximum at 1130 cm -1 to the height of the peak with a maximum at 1165 cm -1 , the value of the ratio of the height of the peak with a maximum at 1130 cm -1 to the height of the peak with a maximum at 1040 cm -1 , the value of the ratio of the height of the peak with a maximum at 1030 cm -1 to the height of the peak with a maximum at 1080 cm -1 and with a ratio value of 1150/1165 equal to 4.59±0.15, a ratio value of 1150/1080 equal to 1.92±0.10, a ratio value of 1140/1160 equal to 2.94±0.11, the value of the ratio 1130/1165 equal to 5.76±0.12, the value of the ratio 1130/1040 equal to 1.84±0.12, the value of the ratio 1030/1080 equal to 1.35±0.05, precancerous disease of the oral mucosa is diagnosed. A disadvantage of the known method is the complex IR spectroscopic study of an oral fluid sample with determination of the height of the peak absorption bands with maxima having multiple quantitative and qualitative digital values, which complicates its application in practice. A method for diagnosing diseases of the oral mucosa is known (RU(11) 2 121144(13) C1, G01N 33/483, publ. 1998.10.27), based on measuring the intensity of the reflected light signal using a laser biophotometer (for example, AFDL-1), the reflected light flux J is determinedVat the site of the suspected inflammation by staining, for this purpose the examined area of the mucosa is lubricated with a solution containing 1 g of crystalline iodine, 2 g of iodide and 20 ml of distilled water, the drug is applied for at least two minutes, after which the intensity of the reflected light signal is measured JANDafter staining. The reflected luminous flux before and after staining differs due to changes in the absorption of light by biological tissue with different staining. Next, the K=J index is determined.B/ JANDand in case of K≠1±0.1, the presence of an inflammatory process is diagnosed, and when K=1±0.1, treatment is stopped. The disadvantage of the known method is the technological complexity of carrying out diagnostic measures using an additional laser biophotometer, which limits its use in clinical dental practice. A method is known for high-quality differential express diagnostics of neoplasms of the oral mucosa based on the content of biomarkers in the patient's oral fluid (RU patent No. 2533241, IPC G01N 33/53, published on 20.11.2014 No. 32), based on determining the content of matrix metalloproteinase 2 (MMP2) and tissue inhibitor of metalloproteinase 1 (TIMP1) in the patient's oral fluid collected before or no earlier than 30 minutes after the patient has eaten, then centrifuging the oral fluid at 3000 rpm for 15 minutes, diluting the oral fluid with saline in a ratio of 1:10 and centrifuging again at 3000 rpm in within 15 minutes, then the patient's oral fluid material ready for testing is placed in a cuvette and a standard enzyme immunoassay method is performed on a plate based on monoclonal antibodies, followed by an analysis of the test results, characterized in that the oral fluid is taken from the patient for neoplasm research, matrix metalloproteinase 2/matrix metalloproteinase 2 (MMP2/MMP2) is selected as a biomarker in the qualitative differential express diagnostics of neoplasms of the mucous membrane of the floor of the oral cavity based on the amount of biomarker content in the oral fluid, and its quantitative content in the patient's oral fluid is determined, while the quantitative content of the biomarker in the oral fluid is matrix metalloproteinase 2/matrix metalloproteinase 2 (MMP2/MMP2). If its content is in the amount of 218-313 ng/ml, papilloma of the mucous membrane of the floor of the oral cavity of the patient is diagnosed, while if the content of tissue inhibitor o